DK2086940T3 - Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol - Google Patents

Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Info

Publication number: DK2086940T3
Authority: DK; Denmark
Prior art keywords: alfa; beta; quinolinethanol; brom; naphthalenyl
Prior art date: 2006-12-05

Application number

DK07847697.5T

Other languages

English (en)

Inventor

Remoortere Peter Jozef Maria Van

Jean Francois Alexandre Lucas Hegyi

Wim Albert Alex Aelterman

Yolande Lydia Lang

Sigrid Carl Maria Stokbroekx

Carina Leys

Anne Faure

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-03

Publication date

2012-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2086940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2012-08-20 Application granted granted Critical

2012-08-20 Publication of DK2086940T3 publication Critical patent/DK2086940T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

DK07847697.5T 2006-12-05 2007-12-03 Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol DK2086940T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06125443		2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en)	2006-12-05	2007-12-03	Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number	Publication Date
DK2086940T3 true DK2086940T3 (da)	2012-08-20

Family

ID=37983588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07847697.5T DK2086940T3 (da)	2006-12-05	2007-12-03	Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Country Status (34)

Country	Link
US (1)	US8546428B2 (da)
EP (1)	EP2086940B1 (da)
JP (2)	JP2010511663A (da)
KR (1)	KR101514700B1 (da)
CN (2)	CN101547904A (da)
AP (1)	AP2498A (da)
AR (1)	AR064149A1 (da)
AU (1)	AU2007328945B2 (da)
BR (1)	BRPI0719693A2 (da)
CA (1)	CA2668512C (da)
CL (1)	CL2007003472A1 (da)
CY (1)	CY1113594T1 (da)
DK (1)	DK2086940T3 (da)
EA (1)	EA017091B9 (da)
ES (1)	ES2387923T3 (da)
HK (1)	HK1214513A1 (da)
HR (1)	HRP20120639T1 (da)
IL (1)	IL199077A (da)
JO (1)	JO2973B1 (da)
ME (1)	ME01456B (da)
MX (1)	MX2009005909A (da)
MY (1)	MY148844A (da)
NO (1)	NO342773B1 (da)
NZ (1)	NZ576485A (da)
PE (1)	PE20081350A1 (da)
PL (1)	PL2086940T3 (da)
PT (1)	PT2086940E (da)
RS (1)	RS52408B (da)
SI (1)	SI2086940T1 (da)
TW (1)	TWI417098B (da)
UA (1)	UA97813C2 (da)
UY (1)	UY30762A1 (da)
WO (1)	WO2008068231A1 (da)
ZA (1)	ZA200903907B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120010216A1 (en) *	2010-07-06	2012-01-12	Brown Arthur M	Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs)	2014-10-16	2016-04-27	Zentiva, K.S.	Soli Bedaquilinu
AU2016212116B2 (en) *	2015-01-27	2021-07-15	Janssen Pharmaceutica Nv	Dispersible compositions
CN106279017A (zh) *	2015-05-21	2017-01-04	重庆圣华曦药业股份有限公司	贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs)	2015-06-09	2016-12-21	Zentiva, K.S.	Sůl bedaquilinu s kyselinou citronovou
CN108349898B (zh) *	2015-10-20	2021-03-23	浙江海正药业股份有限公司	富马酸贝达喹啉的晶型及其制备方法
PT3971177T (pt) *	2016-07-20	2024-07-30	Novartis Ag	Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
CN106316943A (zh) *	2016-07-27	2017-01-11	重庆华邦制药有限公司	富马酸贝达喹啉晶型化合物的精制方法
EP3651736B1 (en)	2017-07-14	2021-06-23	Janssen Pharmaceutica NV	Long-acting formulations
US20220023282A1 (en) *	2018-12-13	2022-01-27	Mannkind Corporation	Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
US20220062319A1 (en)	2019-01-09	2022-03-03	Janssen Pharmaceutica Nv	Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) *	2019-02-08	2020-08-13	Mylan Laboratories Limited	Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) *	2020-07-01	2021-09-17	동아에스티 주식회사	(1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) *	2020-09-15	2023-03-07	北京福元医药股份有限公司	一种贝达喹啉药物制剂
US20230346770A1 (en)	2020-11-12	2023-11-02	Janssen Pharmaceutica Nv	Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en)	2021-02-22	2023-10-24	Mannkind Corp.	Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en)	2022-02-07	2023-08-10	Insmed Incorporated	Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en)	2022-05-31	2023-12-07	Janssen Pharmaceutica Nv	Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) *	2022-07-07	2025-06-24	上海交通大学	含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3237575A1 (de) *	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
GB8824392D0 (en) *	1988-10-18	1988-11-23	Ciba Geigy Ag	Dispersible formulation
TW355683B (en) *	1994-02-17	1999-04-11	Janssen Pharmaceutica Nv	Composition containing micronized nebivolol
JP2001503411A (ja) *	1996-10-28	2001-03-13	ディパートメントオブジアーミー，ユー．エス．ガバメント	抗生物質耐性感染症の処置のための化合物、組成物および方法
IL122026A0 (en) *	1996-10-30	1998-03-10	Lilly Co Eli	Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) *	2002-06-19	2004-11-16	Seiko Epson Corporation	Optical modulator, optical device and projector
RS52431B (sr)	2002-07-25	2013-02-28	Janssen Pharmaceutica N.V.	Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora
AU2002350719A1 (en) *	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ES2306146T3 (es) *	2004-05-28	2008-11-01	Janssen Pharmaceutica Nv	Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
WO2006024667A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) *	2004-12-24	2008-04-28	Янссен Фармацевтика Н.В.	Лечение латентного туберкулёза

2007
- 2007-03-12 UA UAA200904218A patent/UA97813C2/uk unknown
- 2007-12-02 JO JO2007511A patent/JO2973B1/en active
- 2007-12-03 CN CNA2007800448088A patent/CN101547904A/zh active Pending
- 2007-12-03 AU AU2007328945A patent/AU2007328945B2/en active Active
- 2007-12-03 US US12/515,986 patent/US8546428B2/en active Active
- 2007-12-03 CL CL200703472A patent/CL2007003472A1/es unknown
- 2007-12-03 EA EA200970532A patent/EA017091B9/ru active Protection Beyond IP Right Term
- 2007-12-03 WO PCT/EP2007/063186 patent/WO2008068231A1/en not_active Ceased
- 2007-12-03 DK DK07847697.5T patent/DK2086940T3/da active
- 2007-12-03 NZ NZ576485A patent/NZ576485A/en unknown
- 2007-12-03 ES ES07847697T patent/ES2387923T3/es active Active
- 2007-12-03 KR KR1020097011043A patent/KR101514700B1/ko active Active
- 2007-12-03 BR BRPI0719693-8A2A patent/BRPI0719693A2/pt not_active Application Discontinuation
- 2007-12-03 EP EP07847697A patent/EP2086940B1/en active Active
- 2007-12-03 PT PT07847697T patent/PT2086940E/pt unknown
- 2007-12-03 MY MYPI20092284A patent/MY148844A/en unknown
- 2007-12-03 JP JP2009539724A patent/JP2010511663A/ja active Pending
- 2007-12-03 CN CN201510368829.1A patent/CN105012303A/zh active Pending
- 2007-12-03 AP AP2009004870A patent/AP2498A/xx active
- 2007-12-03 ME MEP-2012-95A patent/ME01456B/me unknown
- 2007-12-03 HR HRP20120639TT patent/HRP20120639T1/hr unknown
- 2007-12-03 SI SI200730984T patent/SI2086940T1/sl unknown
- 2007-12-03 CA CA2668512A patent/CA2668512C/en active Active
- 2007-12-03 MX MX2009005909A patent/MX2009005909A/es active IP Right Grant
- 2007-12-03 RS RS20120336A patent/RS52408B/sr unknown
- 2007-12-03 PL PL07847697T patent/PL2086940T3/pl unknown
- 2007-12-04 TW TW096146000A patent/TWI417098B/zh active
- 2007-12-05 PE PE2007001719A patent/PE20081350A1/es active IP Right Grant
- 2007-12-05 UY UY30762A patent/UY30762A1/es active IP Right Grant
- 2007-12-05 AR ARP070105442A patent/AR064149A1/es not_active Application Discontinuation
2009
- 2009-06-02 IL IL199077A patent/IL199077A/en active IP Right Grant
- 2009-06-04 ZA ZA2009/03907A patent/ZA200903907B/en unknown
- 2009-07-06 NO NO20092535A patent/NO342773B1/no unknown
2012
- 2012-08-13 CY CY20121100734T patent/CY1113594T1/el unknown
2014
- 2014-09-19 JP JP2014191134A patent/JP5894239B2/ja active Active
2016
- 2016-03-04 HK HK16102481.4A patent/HK1214513A1/zh unknown

Also Published As

Publication number	Publication date
RS52408B (sr)	2013-02-28
CA2668512A1 (en)	2008-06-12
ZA200903907B (en)	2013-08-28
CN101547904A (zh)	2009-09-30
HRP20120639T1 (hr)	2012-08-31
AR064149A1 (es)	2009-03-18
JO2973B1 (en)	2016-03-15
ES2387923T3 (es)	2012-10-04
HK1214513A1 (zh)	2016-07-29
NO20092535L (no)	2009-08-06
US8546428B2 (en)	2013-10-01
CN105012303A (zh)	2015-11-04
US20100028428A1 (en)	2010-02-04
IL199077A (en)	2016-09-29
CY1113594T1 (el)	2016-06-22
CA2668512C (en)	2015-03-24
PL2086940T3 (pl)	2012-10-31
NZ576485A (en)	2012-01-12
EA200970532A1 (ru)	2009-10-30
MY148844A (en)	2013-06-14
PT2086940E (pt)	2012-08-09
KR101514700B1 (ko)	2015-04-24
CL2007003472A1 (es)	2008-08-22
TWI417098B (zh)	2013-12-01
AP2498A (en)	2012-10-19
SI2086940T1 (sl)	2012-09-28
EA017091B1 (ru)	2012-09-28
PE20081350A1 (es)	2008-09-18
EP2086940A1 (en)	2009-08-12
AU2007328945B2 (en)	2014-04-03
ME01456B (me)	2014-04-20
TW200838527A (en)	2008-10-01
KR20090087020A (ko)	2009-08-14
BRPI0719693A2 (pt)	2013-12-24
JP2010511663A (ja)	2010-04-15
EP2086940B1 (en)	2012-05-16
UA97813C2 (uk)	2012-03-26
AP2009004870A0 (en)	2009-06-30
JP5894239B2 (ja)	2016-03-23
AU2007328945A1 (en)	2008-06-12
UY30762A1 (es)	2008-07-03
EA017091B9 (ru)	2014-10-30
WO2008068231A1 (en)	2008-06-12
NO342773B1 (no)	2018-08-06
JP2015028049A (ja)	2015-02-12
MX2009005909A (es)	2009-06-16

Publication	Publication Date	Title
DK2086940T3 (da)	2012-08-20	Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol
DK2101570T3 (da)	2013-05-27	Tannatsalt af rasagilin
BRPI0722082A2 (pt)	2014-04-01	Ligantes para imagiologia da inervação cardíaca
DE502008000295D1 (de)	2010-02-25	Nockenwelle
DE112007002915A5 (de)	2009-10-15	Verstelleinrichtung
DE502007002976D1 (de)	2010-04-15	Nockenwelle
EP1998019A4 (en)	2013-03-27	THERMOSTAT
BRPI0814314A2 (pt)	2015-05-26	Microbiocidas
ATE449068T1 (de)	2009-12-15	Neue mikrobiozide
DE502007001122D1 (de)	2009-09-03	Humeruskomponente
DK2114147T3 (da)	2012-06-25	Reduktion af bivirkninger af tramadol
EP2029211A4 (en)	2012-12-05	SERVICE LOOP
FR2908035B1 (fr)	2009-05-01	Implant interepineux
DE112007000221A5 (de)	2009-01-15	Abseilvorrichtung
DK2054363T3 (da)	2013-06-03	Asymmetrisk hydrogenering af 1,1,1-trifluoracetone
SE0602723L (sv)	2007-12-17	Belagt skär
DE602007002163D1 (de)	2009-10-08	Weichspülmittel
DK2089708T3 (da)	2012-12-03	Forudsigelige kræft-immunterapi parametre
DE502006005208D1 (de)	2009-12-03	Kochgefäss
DK2046745T3 (da)	2014-01-20	Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
EP2003779A4 (en)	2010-04-14	Pll device
DE502006007220D1 (de)	2010-07-29	Nockenwelle
ITVI20060074A1 (it)	2007-09-18	Struttura di ancoraggio,particolarmente per radiatori
FI20065528A0 (fi)	2006-08-25	Moniresonanssiantenni
ITMI20060760A1 (it)	2007-10-15	Procedimento per il trattamento di tessuti